TY - JOUR
T1 - Central and peripheral α-synuclein in Parkinson disease detected by seed amplification assay
AU - For the Systemic Synuclein Sampling Study
AU - Chahine, Lana M.
AU - Beach, Thomas G.
AU - Adler, Charles H.
AU - Hepker, Monica
AU - Kanthasamy, Anumantha
AU - Appel, Scott
AU - Pritzkow, Sandra
AU - Pinho, Michelle
AU - Mosovsky, Sherri
AU - Serrano, Geidy E.
AU - Coffey, Christopher
AU - Brumm, Michael C.
AU - Oliveira, Luis M.A.
AU - Eberling, Jamie
AU - Mollenhauer, Brit
AU - Dave, Kuldip
AU - Jennings, Danna
AU - Seibyl, John
AU - Arnedo, Vanessa
AU - Riley, Lindsey
AU - Linder, Carly
AU - Foroud, Tatiana
AU - Kopil, Katherine
AU - Russell, David
AU - Hogarth, Penelope
AU - Akhtar, Rizwan
AU - Amara, Amy
AU - Marras, Connie
AU - Visanji, Naomi
AU - Breen, David P.
AU - Crary, John
AU - White, Charles
AU - Munoz, David
AU - Caspell-Garcia, Chelsea
N1 - Funding Information:
S4 study authors (for group authorship): Kuldip Dave, Danna Jennings, John Seibyl, Vanessa Arnedo, Lindsey Riley, Carly Linder, Tatiana Foroud, Katherine Kopil, David Russell, Penelope Hogarth, Rizwan Akhtar, Amy Amara, Connie Marras, Naomi Visanji, David P. Breen, John Crary, Charles White, David Munoz, and Chelsea Caspell-Garcia. DaTscan doses were generously provided in-kind by GE Healthcare. The authors thank the study participants, the S4 Study's medical monitor Dr. Ergun Uc, and the following collaborators and contributors: Jan Hamer (Biorepository), Colleen Mitchell (Biorepository), Dixie Ecklund (Clinical and Statistics Core), Holly Riss (Clinical and Statistics Core), Lucia Sue (Pathology Core), Anthony Intorcia (Pathology Core), Michael Glass (Pathology Core), Jessica Walker (Pathology Core), Lindsey Guilmette (Imaging Core), Vikash Oza (Dermatology Collaborator), David Lott (ENT Collaborator), Ali Keshavarzian (GI Collaborator), Julie Schneider (Pathology Collaborator), Thomas Kremer (Industry Collaborator), Christian Schmauch (Industry Collaborator), Peggy Taylor (Industry Collaborator), Trevis Huff (Clinical and Statistics Core), Danielle Smith (Biorepository),Chaucer Noyes-Lloyd (Study Coordinator), Rachael Purri (Study Coordinator), Brandon Rothberg (Study Coordinator), Courtney Blair (Study Coordinator), K. Rose (Study Coordinator), Madeline Cresswell (Study Coordinator), Amy Duffy (Study Coordinator), and Madeline Potter (Study Coordinator).
Funding Information:
Michael J Fox Foundation. The following authors receive research funding support from the study sponsor (Michael J Fox Foundation): Lana M. Chahine, Thomas G Beach, Charles H. Adler, Monica Hepker, Anumantha Kanthasamy, Scott Appel, Sandra Pritzkow, Michelle Pinho, Sherri Mosovsky, Geidy E. Serrano, Christopher Coffey, Michael C. Brumm, Luis Oliveira, Jamie Eberling, and Brit Mollenhauer. The following authors are employed by the study sponsor (Michael J Fox Foundation): Luis Oliveira and Jamie Eberling.
Publisher Copyright:
© 2023 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
PY - 2023/5
Y1 - 2023/5
N2 - Objectives: Detection of α-synuclein aggregates by seed amplification is a promising Parkinson disease biomarker assay. Understanding intraindividual relationships of α-synuclein measures could inform optimal biomarker development. The objectives were to test accuracy of α-synuclein seed amplification assay in central (cerebrospinal fluid) and peripheral (submandibular gland) sources, compare to total α-synuclein measures, and investigate within-subject relationships. Methods: The Systemic Synuclein Sampling Study aimed to characterize α-synuclein in multiple tissues and biofluids within Parkinson disease subjects (n = 59) and compared to healthy controls (n = 21). Motor and non-motor measures and dopamine transporter scans were obtained. Four measures of α-synuclein were compared: seed amplification assay in cerebrospinal fluid and formalin-fixed paraffin-embedded submandibular gland, total α-synuclein quantified in biofluids using enzyme-linked immunoassay, and aggregated α-synuclein in submandibular gland detected by immunohistochemistry. Accuracy of seed amplification assay for Parkinson disease diagnosis was examined and within-subject α-synuclein measures were compared. Results: Sensitivity and specificity of α-synuclein seed amplification assay for Parkinson disease diagnosis was 92.6% and 90.5% in cerebrospinal fluid, and 73.2% and 78.6% in submandibular gland, respectively. 25/38 (65.8%) Parkinson disease participants were positive for both cerebrospinal fluid and submandibular gland seed amplification assay. Comparing accuracy for Parkinson disease diagnosis of different α-synuclein measures, cerebrospinal fluid seed amplification assay was the highest (Youden Index = 83.1%). 98.3% of all Parkinson disease cases had ≥1 measure of α-synuclein positive. Interpretation: α-synuclein seed amplification assay (cerebrospinal fluid>submandibular gland) had higher sensitivity and specificity compared to total α-synuclein measures, and within-subject relationships of central and peripheral α-synuclein measures emerged.
AB - Objectives: Detection of α-synuclein aggregates by seed amplification is a promising Parkinson disease biomarker assay. Understanding intraindividual relationships of α-synuclein measures could inform optimal biomarker development. The objectives were to test accuracy of α-synuclein seed amplification assay in central (cerebrospinal fluid) and peripheral (submandibular gland) sources, compare to total α-synuclein measures, and investigate within-subject relationships. Methods: The Systemic Synuclein Sampling Study aimed to characterize α-synuclein in multiple tissues and biofluids within Parkinson disease subjects (n = 59) and compared to healthy controls (n = 21). Motor and non-motor measures and dopamine transporter scans were obtained. Four measures of α-synuclein were compared: seed amplification assay in cerebrospinal fluid and formalin-fixed paraffin-embedded submandibular gland, total α-synuclein quantified in biofluids using enzyme-linked immunoassay, and aggregated α-synuclein in submandibular gland detected by immunohistochemistry. Accuracy of seed amplification assay for Parkinson disease diagnosis was examined and within-subject α-synuclein measures were compared. Results: Sensitivity and specificity of α-synuclein seed amplification assay for Parkinson disease diagnosis was 92.6% and 90.5% in cerebrospinal fluid, and 73.2% and 78.6% in submandibular gland, respectively. 25/38 (65.8%) Parkinson disease participants were positive for both cerebrospinal fluid and submandibular gland seed amplification assay. Comparing accuracy for Parkinson disease diagnosis of different α-synuclein measures, cerebrospinal fluid seed amplification assay was the highest (Youden Index = 83.1%). 98.3% of all Parkinson disease cases had ≥1 measure of α-synuclein positive. Interpretation: α-synuclein seed amplification assay (cerebrospinal fluid>submandibular gland) had higher sensitivity and specificity compared to total α-synuclein measures, and within-subject relationships of central and peripheral α-synuclein measures emerged.
UR - http://www.scopus.com/inward/record.url?scp=85151287012&partnerID=8YFLogxK
U2 - 10.1002/acn3.51753
DO - 10.1002/acn3.51753
M3 - Article
C2 - 36972727
AN - SCOPUS:85151287012
SN - 2328-9503
VL - 10
SP - 696
EP - 705
JO - Annals of Clinical and Translational Neurology
JF - Annals of Clinical and Translational Neurology
IS - 5
ER -